Denali Therapeutics Inc. (DNLI) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en South San Francisco, CA, United States. El CEO actual es Ryan J. Watts.
DNLI tiene fecha de IPO 2017-12-08, 443 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $3.2B.
Denali Therapeutics Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutic candidates for neurodegenerative diseases. The company's pipeline includes several clinical-stage programs, such as BIIB122/DNL151, a LRRK2 inhibitor in Phase I/Ib trials for Parkinson's disease, DNL310 for Hunter syndrome, DNL343 for ALS, and SAR443122/DNL758 for cutaneous lupus erythematosus. Denali has established strategic collaborations with leading pharmaceutical and research institutions including Takeda, Genentech, Sanofi, and Harvard University to advance its antisense therapy platform and other neurodegenerative disease treatments. The company was incorporated in 2013 and operates under its current name since March 2015.
